Page Banner

United States Department of Agriculture

Agricultural Research Service

Animal Health
headline bar

Each year, approximately 60 new patents are issued by the U.S. Patent Office for USDA inventions. The Office of Technology Transfer (OTT) transfers these inventions through licenses to the private sector for commercialization. Below are links to the new technologies that are available for licensing. 

Docket

Title

Description

Contact

68.12 NEW

MUTATED SALMONELLA ENTERICA

 

A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated swine, poultry and other animals for a range of S. enterica serovars. The bacteria can be attenuated or inactivated. Vaccines and methods of generating an immune response are included in the invention. PCT Publication No. WO2015103104 A1 Benefits - Provides broad protection against many Salmonellaenterica serovars - Could result in a reduction in the use of antibiotics in animal production for non-therapeutic purposes - DIVA vaccine Applications - Safe and efficacious vaccine to combat various Salmonella enterica to prevent disease in animals and also to reduce subclinical infections in food-producing animals that are a source of foodborne diseases in humans

renee.wagner@ars.usda.gov

47.09 + 73.16

 

COMPOSITIONS AND METHODS FOR REPELLING BLOOD-SUCKING AND BITING INSECTS, TICKS AND MITES

 

Structures, activities and synthetic methods of chromenes and their analogs as repellents that can be used as personal protection against blood sucking and biting insects and arthropods such as mosquitoes, ticks, and fleas. Benefits - Long lasting natural products - Biodegradable

Applications -Plant derived Insect repellent that could potentially be applied to skin, hair and clothing. It could be applied as a spray, cream, ointment, paste or powder with a suitable medium or carrier

thomas.valco@ars.usda.gov   joseph.lipovsky@ars.usda.gov

116.15

 

IN VITRO PARASITE FEEDING SYSTEM

 

The system includes a feeding vessel having an inlet, an outlet, and a membrane positioned across an opening in the vessel. Parasites (preferably ticks) are allowed to attach themselves to the membrane so that as a feeding fluid (preferably blood) is circulated through the vessel, the parasites feed on the feeding fluid through the membrane. Benefits - A simple, flexible, and economical tick feeding system that closely simulates a tick’s preferred host throughout the entire tick life cycle - Standardized, quality controlled vaccine production

Applications - Full tick life cycle system for production of live pathogen stage specific vaccines or testing of anti-tick compounds

david.nicholson@ars.usda.gov

 

35.16

GENETICALLY MODIFIED BABESIA PARASITES EXPRESSING PROTECTIVE TICK ANTIGENS AND USES THEREOF

 

Methods for stable transfection of Babesia parasites with any heterologous DNA and genetically altered Babesia expressing heterologous DNA. One application can be for vaccines conferring immunity against parasitic arthropods. The method involves transfecting s foreign DNA into Babesia resulting in genetically modified parasites that will be able to express foreign genes in animal hosts. Divisional patent application. Parent U.S. patent No. is 9,265,818.

Benefits - Application would be a single dose of a bivalent vaccine - Eliminates the need for recombinant protein production used in vaccines Applications - Facilitate control of both, ticks and tick-borne diseases in animals - For expressing any desired antigen or other protein in animals that are infected with the genetically altered Babesia - For vaccinating cattle in tropical areas of the world where gathering cattle could be a cumbersome procedure

david.nicholson@ars.usda.gov

 

98.11

 

BIOASSAY FOR CELL CONDITIONED MEDIA

 

A novel hybridoma cell line (RMH359) and its use as a cellular bioassay to determine the bioactivity of cell conditioned media (CCM) as a supplement used to support cell survival and promote growth in culture. This bioassay provides a measure of CCM bioactivity in support of hybridoma cells used in the generation and production of monoclonal antibodies.

Benefits The bioassay: - Validates the bioactivity of MCM to be used in hybridoma cell culture - Determines optimal concentration of MCM for addition to hybridoma growth media - Normalizes batch production of MCM Applications - A bioassay that can be used to validate bioactivity and standardize production of CCM such as macrophage conditioned medium (MCM). The RMH359 cell line represents a novel cellular bioassay as its survival is completely dependent on the addition of MCM

david.nicholson@ars.usda.gov

 

127.14

 

DART DELIVERY SYSTEM

 

A remote dart delivery system for accurately delivering a powdered medication and/or vaccine to animals at an extended range of up to 100 yards. The dart delivery system is designed to be fired from a conventional shotgun.

Benefits - Darts are fired from a conventional shot gun so there is no need to purchase a specifically designed gun - The darts contain a drug or vaccine, in a powdered, pelleted, or lyophized state which have a longer shelf-life than a conventional dart delivery system - The system has a unique animal marking system which is incorporated into the design of the dart Applications - Veterinarians and livestock producers to remotely deliver vaccines and powdered medications to livestock without having to purchase a gun designed specifically for the delivery of darts

jeffrey.walenta@ars.usda.gov

 

107.13

 

NOVEL USES OF OIL AND ITS COMPONENTS

 

Novel oils called liamocins from the fungus Aurebasidium pullans are disclosed. The liamocins have anti-bacterial activity with high specificity for Streptococcus spp., Enterococcus spp., and Bacillus spp. Also provided is a method for treating disease caused by bacterial infection in an animal.

Benefits - Potentially could reduce the use of broad spectrum antibiotics and thus the selection for drug resistant pathogens - Liamocins are chemically different than convention antibiotics and may be effective for infections that do not respond to conventional antibiotic therapy

Applications - Treatment of mastitis in dairy cows and other animal diseases caused by Streptococcus spp., Enterococcus spp., and Bacillus spp

renee.wagner@ars.usda.gov

87.13

 

 

 

 

 

 

SPONTANEOUSLY IMMORTALIZED AVIAN CELL LINE

 

 

 

 

 

 

A spontaneously immortalized avian cell line, designated ZS-1, derived from the primary chicken embryonic fibroblasts.

Benefits - The immortal cell line is free of avian leukosis virus (ALV) and yet susceptible to all subgroups of ALV, including subgroup E - Supports virus replication

Applications - Production of viral agents, e.g., recombinant viral agents, expression of recombinant proteins, diagnostic assays of pathological specimens, etc.

renee.wagner@ars.usda.gov

173.09

 

 

 

 

 

 

 

 

 

 

PHAGE TWORT ENDOLYSIN CHAP DOMAIN IS LYTIC FOR STAPHYLOCOCCUS AUREUS

 

 

 

 

 

 

 

 

 

 

A potential antimicrobial treatment to combat S. aureus mastitis. The invention is a nucleic acid sequence encoding an antimicrobial peptidoglycan hydrolase polypeptide, the Phage Twort (PlyTW) endolysin, a protein that attacks the cell wall peptidoglycan of S. aureus. Both the full length phage Twort endolysin PlyTW and truncated PlyTW (PlyTW Δ172-373) lyse live S. aureus, including multidrug-resistant staphylococci. Truncated PlyTW (PlyTW Δ172-373) lacks the amidase domain of the full length PlyTW, but has higher lytic activity.   Benefits - Useful as an alternative antibiotic treatment to the multidrug-resistant S. aureus

Applications - Treatment for mastitis as well as for infection and other human diseases caused by S. Aureus - Potentially used to produce novel protein fusion antimicrobials believed to be refractory to antibiotic resistance development

jim.poulos@ars.usda.gov

 

5.12            

 

 

 

 

 

 

 

 

 

 

 

ANTIMICROBIAL ENZYME FUSIONS REDUCE RESISTANCE AND KILL INTRACELLULAR STAPHYLOCOCCUS AUREUS

 

 

 

 

 

 

 

 

 

Engineered triple-acting staphylolytic peptidoglycan hydrolases where three unique antimicrobial activities from two parental proteins are combined into a single fusion protein, effectively reducing the incidence of resistant strain development. The fusion protein reduced colonization by S. aureus in a rat nasal colonization model, surpassing the efficacy of either parental protein. Benefits - Modification of the triple-acting lytic construct with a protein transduction domain significantly enhanced both biofilm eradication and the ability to kill intracellular Staphylococcus aureus as demonstrated in cultured cells, and mouse models of staphylococcal mastitis and osteomyelitis - Alternative antibiotic treatment to the multidrug-resistant S. aureus

Applications - A new antimicrobial to combat S. aureus infection in animals and humans

jim.poulos@ars.usda.gov

186.11 + 79.14

 

 

 

 

 

 

HIGH AFFINITY MONOCLONAL ANTIBODIES FOR DETECTION OF SHIGA TOXIN 2 (STX2)

 

 

 

 

 

 

High affinity monoclonal antibodies against Shiga toxin strain Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample.

 

Benefits

- The hybridoma cell lines produce monoclonal antibodies that detect all four variants of Stx2

- Immunoassays are rapid, highly specific and sensitive

 

Applications

- Basis for developing a sensitive immunoassays for detecting variants for Shiga toxin 2

- Immunoassys could be used for monitoring and source-tracking food supplies as well as monitoring contamination of clinical and environmental samples such as feces, soil, air, and water.

 david.nicholson@ars.usda.gov

2.14                      

METHOD FOR BED BUG CONTROL

A low oxygen treatment method for bed bug control. The method comprises placing a bed-bug contaminated object in a sealable enclosure and establishing reduced oxygen (<3%) conditions for an amount of time sufficient to control bed bugs.

Benefits

- Environmental friendly method that does not rely on heat, pesticides or insecticides

- Unlikely to have any negative impact on treated objects

 

Applications

- An effective and safe treatment to bed bug problems

 david.nicholson@ars.usda.gov

35.14                

INTRAVITREAL INJECTION OF A CHIMERIC PHAGE ENDOLYSIN PLY187; PROTECTION FROM STAPHYLOCOCCUS AUREUS ENDOPHTHALMITIS

A novel antimicrobial protein derived from a virus that infects bacteria has been tested and shown to reduce or eradicate staphylococcal bacteria infecting the eye ball in a mouse model of eye infection. The antimicrobial protein evaluated is Ply187AN-KSH3b, a chimeric phage endolysin derived from the Ply187 prophage. Intravitreal injection in C57BL/6 mouse eyes of chimeric Ply187AN-KSH3b (both at 6 and 12 h post infection) significantly improved the outcome of staphylococcal endophthalmitis, preserved retinal structural integrity, and maintained visual function. Phage lysin treatment significantly reduced the bacterial burden and the levels of inflammatory cytokines and neutrophil infiltration in the eyes.

 

Benefits

- Staphylococci are notoriously prone to antibiotic resistance development. This protein works on the outside of the pathogen, thereby avoiding many resistance mechanisms that conventional intracellular antibiotics lack.

- This protein works through the digestion of the peptidoglycans which result in the lysis of the bacterial cells. This mode of action is especially important due to the ‘immune privileged’ status of the eye, where unlike most other body cavities, immune cells do not invade

 

Applications

- There is a need for antimicrobial treatments into the eyeball to cure staphylococcus infections of the eye, especially following cataract surgery

jim.poulos@ars.usda.gov


Last Modified: 9/8/2016
Footer Content Back to Top of Page